Spinner CD, Gottlieb RL, Criner GJ, Arribas López J R, Cattelan A M, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai L Y A, Roestenberg M, Tsang O T Y, Bernasconi E, Le Turnier P, Chang S-C, SenGupta D, Hyland RH, Osinusi AO, Cao H, et al.
Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown.
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
